Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

Ghrelin is an orexigenic peptide predominantly secreted by the stomach.

Ghrelin plasma levels rise before meal ingestion and sharply decline afterwards, but the mechanisms controlling ghrelin secretion are largely unknown.

Who Took Part

The abstract describes 14 volunteers taking part.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The volunteers were allocated by chance, so the Ghrelin group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Ghrelin could be set against what happens without it.

After 30 min, a solid test meal was served.

Venous blood was drawn frequently for the determination of glucose, insulin, C-peptide, GLP-1 and ghrelin.

What Was Measured

Ghrelin plasma levels rise before meal ingestion and sharply decline afterwards, but the mechanisms controlling ghrelin secretion are largely unknown.

Topics PubMed links to this paper include Blood Glucose, Energy Metabolism, Ghrelin, Glucagon-Like Peptide 1, Insulin, Insulin Secretion and Peptide Hormones.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Ghrelin in 14 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Regulatory peptides), a journal based in Netherlands.

More context: the Ghrelin compound page, all human trials.